Clinical Trials Directory

Trials / Completed

CompletedNCT00388128

Caffeine and Intermittent Claudication

Effects of Caffeine in Patients With Intermittent Claudication.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the change in Walking capacity after an intake of caffeine. The study design is cross-over and follow-up of 80 patients with leg pain caused by narrowing of their leg arteries, Peripheral Vascular Disease (PAD), stage II. Half of all will be revascularised, follow up will be after 3 months. It is hypothesized that caffeine (6mg/kg) can be a cheap, safe drug before walking exercise. Primary endpoint is maximum walking distance (MWD), treadmill-testing,(constant load, 0%,2m/h). Secondary endpoints are pain free walking distance (PWD), maximum muscle strength, endurance, reaction speed, balance, cognitive function, health related quality of life (SF-36).

Detailed description

PAD has a prevalence of 15-20 % in an elderly (\>50) western population. PAD can not be seen in isolation but represents the peripheral manifestation of a generalized artherosclerosis. The co-morbidity with coronary or cerebralartherosclerosis depends on the degree of severity of PAD, the relative risk of a death (predominantly cardiac) is increased by a factor 4. From af medical and a socio-economic point of view there is the need to control the PAD complication rate and related treatment costs as effectively as possible. The aim of any treatment of intermittent claudication is a clinically relevant improvement in the patient´s mobility and quality of life. There is agreement, that physical training does improve the collateralisation of vascular lesions, the rheologic properties of blood and lead to a shift from glycolytic to oxidative muscle fibers in the working musculature which increases the capillary density. The effect of physical training is also to modify the patients risk factor profile, even moderate training increase the insulin receptor sensitivity and the fibrinolytic activity and decrease the dLDL/HDL ratio and the diastolic blood pressure in hypertensive patients - and thereby decrease the overall cardiac mortality. This is a Phase 3, 12-week, double-blind, randomized, placebo-controlled cross-over and a follow-up study with 80 patients with intermittent claudication, half of which will be revascularized. The objectives of this study are to evaluate the efficacy of caffeine (6mg/kg)and the revascularisation procedure. The primary end-point will be maximal walking distance (MWD) in both groups of patients. Other efficacy measures will include claudication onset time (PWD), changes in Ankle Brachial Index (ABI), Quality of Life (QoL), cognitive function, plasma response of Vascular Endothelian Growth Factor (VEGF, FGF). Safety variables will include routine hematology parameters and adverse events.

Conditions

Interventions

TypeNameDescription
DRUGCaffeine 6mg/kgCapsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing

Timeline

Start date
2006-09-01
Primary completion
2009-05-01
Completion
2009-09-01
First posted
2006-10-13
Last updated
2011-06-09

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00388128. Inclusion in this directory is not an endorsement.